Scholarlink

<p>Despite endocrine therapy (ET), approximately 20–40% of Stage I–III estrogen receptor-positive breast cancer (ER + BC) patients experience recurrence. Recurrence while on ET is indicative of ET resistance. This study aimed to identify differentially expressed genes (DEGs) associated with recurrence during ET (ET resistance) and to explore gene expression differences across PAM50 molecular subtypes. Eighty tumor specimens from 79 patients treated at the City of Hope Comprehensive Cancer Center (2012–2016) were analyzed using NanoString technology. Fourteen patients (17.7%) experienced recurrence over a median follow-up of 68&#xa0;months (range 35–104&#xa0;months). Key upregulated DEGs in the recurrence group included <i>EZH2</i> (log2 fold change[log2FC]: 0.67, <i>p</i> = 0.0017), <i>WNT11</i> (log2FC: 1.08, <i>p</i> = 0.0088), <i>ITGB6</i> (log2FC: 0.80, <i>p</i> = 0.0312), and <i>TOP2A</i> (log2FC: 0.79, <i>p</i> = 0.0381). Downregulated DEGs included <i>SNAI2</i> (log2FC: −&#xa0;0.63, <i>p</i> = 0.0055), <i>ITPR1</i> (log2FC: −&#xa0;0.75, <i>p</i> = 0.0083), <i>CD10</i> (log2FC: −&#xa0;0.70, <i>p</i> = 0.0092), <i>PTEN</i> (log2FC: −&#xa0;0.29, <i>p</i> = 0.0163), <i>VRD</i> (log2FC: −&#xa0;0.46, <i>p</i> = 0.0184), and <i>WNT5A</i> (log2FC: −&#xa0;0.76, <i>p</i> = 0.0272). <i>EZH2</i> and <i>TOP2A</i> were positively correlated with proliferation scores, while <i>WNT11</i> and <i>ITGB6</i> emerged as potential biomarkers independently associated with recurrence. These findings suggest novel biomarker candidates that could help overcome ET resistance, reduce recurrence, and improve outcomes in ER + BC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Gene expression associated with endocrine therapy resistance in estrogen receptor-positive breast cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年2月28日

查看全文
  • Veronica Jones,
  • Hongwei Holly Yin,
  • Yate-Ching Yuan,
  • Yongzhe Wang,
  • Sierra Min Li,
  • Dana Aljaber,
  • Angelica Sanchez,
  • Christine Quinones,
  • Dan Schmolze,
  • Yuan Yuan,
  • Joanne Mortimer,
  • Lisa Yee,
  • Laura Kruper,
  • Tijana Jovanovic-Talisman,
  • Jerneja Tomsic,
  • Nancy Sanchez,
  • Tanya Chavez,
  • Ruth M. O’Regan,
  • Qamar J. Khan,
  • Melissa Davis,
  • Kevin Kalinsky,
  • Jane Meisel,
  • Rick Kittles,
  • Lorna Rodriguez-Rodriguez,
  • Victoria Seewaldt

摘要

Despite endocrine therapy (ET), approximately 20–40% of Stage I–III estrogen receptor-positive breast cancer (ER + BC) patients experience recurrence. Recurrence while on ET is indicative of ET resistance. This study aimed to identify differentially expressed genes (DEGs) associated with recurrence during ET (ET resistance) and to explore gene expression differences across PAM50 molecular subtypes. Eighty tumor specimens from 79 patients treated at the City of Hope Comprehensive Cancer Center (2012–2016) were analyzed using NanoString technology. Fourteen patients (17.7%) experienced recurrence over a median follow-up of 68 months (range 35–104 months). Key upregulated DEGs in the recurrence group included EZH2 (log2 fold change[log2FC]: 0.67, p = 0.0017), WNT11 (log2FC: 1.08, p = 0.0088), ITGB6 (log2FC: 0.80, p = 0.0312), and TOP2A (log2FC: 0.79, p = 0.0381). Downregulated DEGs included SNAI2 (log2FC: − 0.63, p = 0.0055), ITPR1 (log2FC: − 0.75, p = 0.0083), CD10 (log2FC: − 0.70, p = 0.0092), PTEN (log2FC: − 0.29, p = 0.0163), VRD (log2FC: − 0.46, p = 0.0184), and WNT5A (log2FC: − 0.76, p = 0.0272). EZH2 and TOP2A were positively correlated with proliferation scores, while WNT11 and ITGB6 emerged as potential biomarkers independently associated with recurrence. These findings suggest novel biomarker candidates that could help overcome ET resistance, reduce recurrence, and improve outcomes in ER + BC.